A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 01 May 2018
At a glance
- Drugs Pemetrexed (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PARAMOUNT
- Sponsors Eli Lilly
- 18 Oct 2017 Results of descriptive safety analysis from three randomised trials (PRONOUNCE, PARAMOUNT and KEYNOTE-021 Cohort G) presented at the 18th World Conference on Lung Cancer.
- 31 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 11 Oct 2016 Results of pooled analysis of three phase III trials (JMDB, PARAMOUNT and JMII; n=1064) were presented at the 41st European Society for Medical Oncology Congress
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History